Clinical Research

Phenotypic and genetic analysis of an adult cohort with extreme obesity

Article metrics

Abstract

Context:

Adult extreme obesity (EO) is a growing health concern. The prevalence of known obesity associated co-morbidities namely cardio-metabolic and neuro-psychiatric disease in EO is not fully established. The contribution of pathogenic genetic variants, previously implicated in early childhood onset obesity, to adult EO is also not established.

Objective:

We undertook phenotypic and genetic analysis of adult patients with extreme obesity (EO, BMI > 50). Specifically, we assessed the prevalence of eating disorders, cardio-metabolic, and neuro-psychiatric disease and the presence of pathogenic variants in known monogenic obesity genes.

Design:

A total of 55 patients with EO from a single site bariatric surgery referral program were assessed for the presence of eating disorders, cardio-metabolic, and neuro-psychiatric disease. The 54 obese (O) patients with a BMI < 50 from the same program were identified for phenotypic comparison. The 45 EO patients underwent whole exome sequencing to identify deleterious variants in known monogenic obesity genes.

Outcomes:

(1) Presence of eating disorders, cardio-metabolic, and neuro-psychiatric disease in EO compared to O. (2) Onset of obesity in the EO group. (3) Presence of deleterious variants in genes previously implicated in monogenic obesity in the EO group.

Results:

The EO group had higher prevalence of lifetime neuro-psychiatric disease (67.3% vs. 37%, p = 0.001) and sleep apnea (74.6% vs. 51.9%, p = 0.01) but lower prevalence of type 2 diabetes (30.1% vs. 50%, p = 0.045) compared to O. There were no significant differences in binge eating, dyslipidemia, hypertension, and cardiac disease. In the EO group, we found previously unreported singleton variants in NTRK2 (pS667W, bio-informatically predicted to be deleterious) and BDNF (pE23K). No previously confirmed loss of function variants in monogenic obesity genes were found.

Conclusions:

Adults with EO have significantly increased prevalence of neuro-psychiatric disease and a possibly lower burden of type 2 diabetes compared to less obese patients. Known monogenic causes of obesity were not highly prevalent in this cohort. Further studies are warranted to confirm these preliminary findings.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Collaborators GBDO, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377:13–27.

  2. 2.

    Twells LK, Gregory DM, Reddigan J, Midodzi WK. Current and predicted prevalence of obesity in Canada: a trend analysis. CMAJ Open. 2014;2:E18–26.

  3. 3.

    Look ARG, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.

  4. 4.

    Avila C, Holloway AC, Hahn MK, Morrison KM, Restivo M, Anglin R, et al. An overview of links between obesity and mental health. Curr Obes Rep. 2015;4:303–10.

  5. 5.

    Goodarzi MO. Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. Lancet Diabetes Endocrinol. 2018;6:223–36.

  6. 6.

    van der Klaauw AA, Farooqi IS. The hunger genes: pathways to obesity. Cell. 2015;161:119–32.

  7. 7.

    Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341:879–84.

  8. 8.

    Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348:1085–95.

  9. 9.

    Calton MA, Ersoy BA, Zhang S, Kane JP, Malloy MJ, Pullinger CR, et al. Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. Hum Mol Genet. 2009;18:1140–7.

  10. 10.

    Lubrano-Berthelier C, Dubern B, Lacorte JM, Picard F, Shapiro A, Zhang S, et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metab. 2006;91:1811–8.

  11. 11.

    Larsen LH, Echwald SM, Sorensen TI, Andersen T, Wulff BS, Pedersen O. Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity. J Clin Endocrinol Metab. 2005;90:219–24.

  12. 12.

    Thearle MS, Muller YL, Hanson RL, Mullins M, Abdussamad M, Tran J, et al. Greater impact of melanocortin-4 receptor deficiency on rates of growth and risk of type 2 diabetes during childhood compared with adulthood in Pima Indians. Diabetes. 2012;61:250–7.

  13. 13.

    Grupski AE, Hood MM, Hall BJ, Azarbad L, Fitzpatrick SL, Corsica JA. Examining the Binge eating scale in screening for binge eating disorder in bariatric surgery candidates. Obes Surg. 2013;23:1–6.

  14. 14.

    Schneider KL, Panza E, Appelhans BM, Whited MC, Oleski JL, Pagoto SL. The emotional eating scale. Can a self-report measure predict observed emotional eating? Appetite. 2012;58:563–6.

  15. 15.

    Chung F, Abdullah HR, Liao P. STOP-bang questionnaire: a practical approach to screen for obstructive sleep apnea. Chest. 2016;149:631–8.

  16. 16.

    Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33.

  17. 17.

    Hendricks AE, Bochukova EG, Marenne G, Keogh JM, Atanassova N, Bounds R, et al. Rare variant analysis of human and rodent obesity genes in individuals with severe childhood obesity. Sci Rep. 2017;7:4394.

  18. 18.

    Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–91.

  19. 19.

    Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–5.

  20. 20.

    Yeo GS, Connie Hung CC, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci. 2004;7:1187–9.

  21. 21.

    Gray J, Yeo GS, Cox JJ, Morton J, Adlam AL, Keogh JM, et al. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes. 2006;55:3366–71.

  22. 22.

    Han JC, Liu QR, Jones M, Levinn RL, Menzie CM, Jefferson-George KS, et al. Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N Engl J Med. 2008;359:918–27.

  23. 23.

    Clement K, Biebermann H, Farooqi IS, Van der Ploeg L, Wolters B, Poitou C et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24:551–555.

  24. 24.

    Pearce LR, Joe R, Doche ME, Su HW, Keogh JM, Henning E, et al. Functional characterization of obesity-associated variants involving the alpha and beta isoforms of human SH2B1. Endocrinology. 2014;155:3219–26.

  25. 25.

    Heid IM, Vollmert C, Kronenberg F, Huth C, Ankerst DP, Luchner A, et al. Association of the MC4R V103I polymorphism with the metabolic syndrome: the KORA Study. Obesity. 2008;16:369–76.

  26. 26.

    Doche ME, Bochukova EG, Su HW, Pearce LR, Keogh JM, Henning E, et al. Human SH2B1 mutations are associated with maladaptive behaviors and obesity. J Clin Invest. 2012;122:4732–6.

  27. 27.

    Bonnefond A, Keller R, Meyre D, Stutzmann F, Thuillier D, Stefanov DG, et al. Eating Behavior, Low-Frequency Functional Mutations in the Melanocortin-4 Receptor (MC4R) Gene, and Outcomes of Bariatric Operations: A 6-Year Prospective Study. Diabetes Care. 2016;39:1384–92.

  28. 28.

    Jagielski AC, Brown A, Hosseini-Araghi M, Thomas GN, Taheri S. The association between adiposity, mental well-being, and quality of life in extreme obesity. PLoS One. 2014;9:e92859.

  29. 29.

    Pitzul KB, Jackson T, Crawford S, Kwong JC, Sockalingam S, Hawa R, et al. Understanding disposition after referral for bariatric surgery: when and why patients referred do not undergo surgery. Obes Surg. 2014;24:134–40.

  30. 30.

    Sala M, Haller DL, Laferrere B, Homel P, McGinty JJ. Predictors of attrition before and after bariatric surgery. Obes Surg. 2017;27:548–51.

  31. 31.

    Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery. Endocr Pract. 2013;19:337–72.

  32. 32.

    Neovius M, Bruze G, Jacobson P, Sjoholm K, Johansson K, Granath F, et al. Risk of suicide and non-fatal self-harm after bariatric surgery: results from two matched cohort studies. Lancet Diabetes Endocrinol. 2018;6:197–207.

  33. 33.

    King WC, Chen JY, Courcoulas AP, Dakin GF, Engel SG, Flum DR, et al. Alcohol and other substance use after bariatric surgery: prospective evidence from a U.S. multicenter cohort study. Surg Obes Relat Dis. 2017;13:1392–402.

  34. 34.

    Wolf AM, Buffington C, Beisiegel U. Comparison of metabolic risk factors between severely and very severely obese patients. Obes (Silver Spring). 2006;14:2177–83.

  35. 35.

    Drapeau V, Lemieux I, Richard D, Bergeron J, Tremblay A, Biron S, et al. Metabolic profile in severely obese women is less deteriorated than expected when compared to moderately obese women. Obes Surg. 2006;16:501–9.

  36. 36.

    Vinciguerra F, Baratta R, Farina MG, Tita P, Padova G, Vigneri R, et al. Very severely obese patients have a high prevalence of type 2 diabetes mellitus and cardiovascular disease. Acta Diabetol. 2013;50:443–9.

  37. 37.

    Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013;1281:51–63.

  38. 38.

    Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281:64–91.

  39. 39.

    Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49:17–26.

  40. 40.

    Fabbrini E, Yoshino J, Yoshino M, Magkos F, Tiemann Luecking C, Samovski D, et al. Metabolically normal obese people are protected from adverse effects following weight gain. J Clin Invest. 2015;125:787–95.

  41. 41.

    Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220–34.

  42. 42.

    Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346:570–8.

  43. 43.

    Zhang Y, Sowers JR, Ren J. Targeting autophagy in obesity: from pathophysiology to management. Nat Rev Endocrinol. 2018;14:356–376.

  44. 44.

    Lee YS, Wollam J, Olefsky JM. An integrated view of immunometabolism. Cell. 2018;172:22–40.

  45. 45.

    Wang DD, Hu FB. Precision nutrition for prevention and management of type 2 diabetes. Lancet Diabetes Endocrinol. 2018;6:416–26.

  46. 46.

    Magi R, Manning S, Yousseif A, Pucci A, Santini F, Karra E, et al. Contribution of 32 GWAS-identified common variants to severe obesity in European adults referred for bariatric surgery. PLoS One. 2013;8:e70735.

  47. 47.

    Abadi A, Alyass A, Robiou du Pont S, Bolker B, Singh P, Mohan V, et al. Penetrance of polygenic obesity susceptibility loci across the body mass index distribution. Am J Hum Genet. 2017;101:925–38.

  48. 48.

    Kuhnen P, Clement K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375:240–6.

  49. 49.

    Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med. 2007;356:237–47.

  50. 50.

    Miller KA, Twigg SR, McGowan SJ, Phipps JM, Fenwick AL, Johnson D, et al. Diagnostic value of exome and whole genome sequencing in craniosynostosis. J Med Genet. 2017;54:260–8.

  51. 51.

    Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K, et al. Large, rare chromosomal deletions associated with severe early-onset obesity. Nature. 2010;463:666–70.

  52. 52.

    Pettersson M, Viljakainen H, Loid P, Mustila T, Pekkinen M, Armenio M, et al. Copy number variants are enriched in individuals with early-onset obesity and highlight novel pathogenic pathways. J Clin Endocrinol Metab. 2017;102:3029–39.

  53. 53.

    Turcot V, Lu Y, Highland HM, Schurmann C, Justice AE, Fine RS, et al. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nat Genet. 2018;50:26–41.

  54. 54.

    Mace A, Tuke MA, Deelen P, Kristiansson K, Mattsson H, Noukas M, et al. CNV-association meta-analysis in 191,161 European adults reveals new loci associated with anthropometric traits. Nat Commun. 2017;8:744.

Download references

Acknowledgements

This work has been funded by Toronto General Hospital Research Institute and Diabetes Canada. PS is a recipient of a Diabetes Action Canada Post-Doctoral Fellowship. SD is a recipient of a Diabetes Canada New Investigator Award and Banting and Best Diabetes Center, Toronto Dennis Scholarship. The authors would like to thank Christina Drake, RN and Suzana Tavares, RN for their help in recruiting and assessing patients.

Author contributions

SD, SSo, AP, PS, AB, TJ, AO, DU, JA designed the study. SD, PS, SSu, and SJL. SD and PS wrote the manuscript with input from all the authors. SD is the guarantor of this work.

Author information

Correspondence to Satya Dash.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stahel, P., Sud, S.K., Lee, S.J. et al. Phenotypic and genetic analysis of an adult cohort with extreme obesity. Int J Obes 43, 2057–2065 (2019) doi:10.1038/s41366-018-0209-8

Download citation